NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock Price, News & Analysis $12.14 -0.12 (-0.98%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$12.12 -0.02 (-0.16%) As of 09/18/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Intellia Therapeutics Stock (NASDAQ:NTLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Intellia Therapeutics alerts:Sign Up Key Stats Today's Range$11.87▼$12.4750-Day Range$10.67▼$13.5152-Week Range$7.95▼$28.25Volume8.62 million shsAverage Volume3.56 million shsMarket Capitalization$1.70 billionP/E RatioN/ADividend YieldN/APrice Target$20.98Consensus RatingHold Company Overview Intellia Therapeutics, Inc. is a biotechnology company focused on developing curative treatments using CRISPR-based gene-editing technology. The company’s approach is designed to make targeted changes to disease-associated genes, including through in vivo therapies that edit genes directly inside the body. Intellia’s pipeline includes NTLA-2001, an investigational treatment designed to address transthyretin amyloidosis by editing the TTR gene, and NTLA-2002, an investigational therapy targeting hereditary angioedema through editing of the KLKB1 gene. The company is also developing additional programs in genetic diseases and other serious conditions. These candidates remain investigational and have not been established as safe or effective by regulatory authorities. Founded in 2014, Intellia is headquartered in Cambridge, Massachusetts. The company was co-founded by Nobel Prize-winning scientist Jennifer Doudna and has collaborated with Regeneron Pharmaceuticals on the development of certain CRISPR-based medicines. John M. Leonard has served as Intellia’s president and chief executive officer since 2018.AI Generated. May Contain Errors. Read More Intellia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreNTLA MarketRank™: Intellia Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 431st out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingIntellia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 1 strong buy rating, 10 buy ratings, 8 hold ratings, and 4 sell ratings.Upside PotentialIntellia Therapeutics has a consensus price target of $20.98, representing about 72.8% upside from its current price of $12.14.Amount of Analyst CoverageIntellia Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intellia Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intellia Therapeutics are expected to grow in the coming year, from ($3.21) to ($2.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Intellia Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted32.49% of the float of Intellia Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 12.89, which indicates bearish sentiment.Change versus previous monthShort interest in Intellia Therapeutics has recently decreased by 2.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.20 News SentimentIntellia Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Intellia Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 14 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.MarketBeat Follows10 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $128,502.00 in company stock.Percentage Held by Insiders3.50% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intellia Therapeutics' insider trading history. Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NTLA Stock News HeadlinesIntellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comCitizens Jmp Reaffirms Market Outperform Rating for Intellia Therapeutics (NASDAQ:NTLA)September 11, 2026 | americanbankingnews.comThe Last Gold Bull Market?Former CIA and Pentagon official Jim Rickards says the current gold bull market could be its last. Investment demand for gold rose 84 percent last year, according to Kitco, and Rickards projects prices could climb toward 10,000 dollars within 12 months. Rickards has identified a 2 dollar gold stock tied to a September 30 catalyst that he believes is positioned for major gains as this trend accelerates.September 20 at 1:00 AM | Paradigm Press (Ad)Wedbush Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $13.00September 11, 2026 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Intellia Therapeutics (NASDAQ:NTLA)September 11, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)September 10, 2026 | theglobeandmail.comWedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral RatingSeptember 8, 2026 | marketscreener.comMIntellia's Lonvo-z BLA Gets FDA Priority Review For Hereditary Angioedema; PDUFA Set For March 2027September 8, 2026 | rttnews.comSee More Headlines NTLA Stock Analysis - Frequently Asked Questions How have NTLA shares performed this year? Intellia Therapeutics' stock was trading at $8.99 at the start of the year. Since then, NTLA stock has increased by 35.0% and is now trading at $12.14. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.00. Intellia Therapeutics's revenue was down 46.4% compared to the same quarter last year. Read the conference call transcript. When did Intellia Therapeutics IPO? Intellia Therapeutics (NTLA) raised $102 million in an initial public offering on Friday, May 6th 2016. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' top institutional shareholders include BlackRock Inc. (11.03%), Bank of America Corp DE (0.70%), Connor Clark & Lunn Investment Management Ltd. (0.64%) and Bank of New York Mellon Corp (0.29%). Insiders that own company stock include John M Leonard, Edward J Dulac III, William J Chase, James Basta, Birgit C Schultes, Eliana Clark, Michael P Dube, David Lebwohl, Laura Sepp-Lorenzino, Glenn Goddard and Jesse Goodman. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW), Meta Platforms (META) and Edwards Lifesciences (EW). Company Calendar Last Earnings8/06/2026Today9/20/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 NTLA's financial health is in the Green zone, according to TradeSmith. NTLA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NTLA CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees377Year Founded2014Price Target and Rating Average Price Target for Intellia Therapeutics$20.98 High Price Target$49.00 Low Price Target$5.00 Potential Upside/Downside+72.8%Consensus RatingHold Rating Score (0-4)2.35 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)($3.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$412.69 million Net Margins-672.16% Pretax Margin-672.16% Return on Equity-57.79% Return on Assets-47.29% Debt Debt-to-Equity RatioN/A Current Ratio6.65 Quick Ratio6.65 Sales & Book Value Annual Sales$67.67 million Price / Sales25.14 Cash FlowN/A Price / Cash FlowN/A Book Value$5.80 per share Price / Book2.09Miscellaneous Outstanding Shares140,130,000Free Float135,223,000Market Cap$1.70 billion OptionableOptionable Beta1.82 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:NTLA) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe Last Gold Bull Market?Former CIA and Pentagon official Jim Rickards says the current gold bull market could be its last. Investment ...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredNo Wallstreet. No Advisor. No Problem.Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
